Signaling Lymphocytic Activation Molecule Family, Member 1 (SLAMF1)

Tatsuo et al. (2000) found that in MV-resistant cell lines infection with clinical MV and expression of SLAM, but not CD46, caused cytopathic effects (CPE). Likewise, anti-SLAM antibody protected cells from CPE when challenged with MV. Lymphoid cell lines expressing SLAM, but not lymphoid and myelomonocytic cell lines devoid of SLAM, were shown to be susceptible to MV. Tatsuo et al. (2000) noted that the expression of SLAM on activated B and T lymphocytes correlates with the pathology of MV infection in humans and monkeys, in which lymphoid organs are the chief sites of MV replication. They proposed that binding of MV to SLAM may impair the signaling functions of SLAM in lymphocyte activation and inhibit Th0/Th1 cytokine production, thereby promoting Th2 cytokine production.